CRVO - NASDAQ
CervoMed Inc.
$5.50
-0.36%CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
At a Glance
Live SnapshotCervoMed Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
CervoMed Inc. Cash Flow Statement
CRVO • NASDAQ
| CervoMed Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 | Dec 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-16.3M | -2.2M | -5.8M | -24.1M | -14.2M | -11.8M | -18.4M | -1.4M | -18M | -6.7M | -14.4M | -2.5M | -6.8M | -23M | -8.4M | -3.4M | -2.1M | -60.8K | -48.1K | 0.0 | |
0.0 | 0.0 | 0.0 | 93.4K | 103.2K | 97.9K | 110.4K | 68K | 25.3K | 8.3K | 566.3K | 118.3K | 164K | 119.8K | 49.7K | 47.2K | 55.9K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -443.9K | -1.7M | 332.9K | -437.3K | -1.1M | -364.8K | 0.0 | -2.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.4M | 407.6K | 333.8K | 897.3K | 736.1K | 0.0 | 0.0 | 0.0 | 0.0 | 594.2K | 1.6M | 2.2M | 3.8M | 0.0 | 1.4M | 158.1K | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.2M | -5.4M | 2.5M | 8.7M | 0.0 | 515.4K | 8.7M | -5.9M | 6.3M | 313.6K | 8.8M | -3.3M | -5M | 10.8M | 4.3M | 1.8M | 1.5M | 0.0 | 0.0 | -94.9K | |
-440.7K | -261.4K | 379.9K | 356.4K | 1.5M | 994.4K | -276.9K | -2.3M | 1.3M | 617.8K | -2.8M | 2.2M | 3.6M | 64.1K | 728.3K | 336.3K | -1.1K | 60.8K | 48.1K | 19.9K | |
-16.5M | -7.4M | -2.6M | -14.5M | -13.6M | -9.9M | -10.8M | -12.3M | -10.8M | -5.2M | -9M | -1.2M | -4.3M | -12M | -2M | -1.1M | -506K | 0.0 | 0.0 | -75K | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -447.8K | -2.3K | -40.3K | -50.9K | (0.0) | (0.0) | -125K | -13.6K | -1.1K | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (4K) | (0.0) | (0.0) | (0.0) | (0.0) | (8.5M) | -250K | (0.0) | (0.0) | (0.0) | -860.9K | (0.0) | -212K | (0.0) | (0.0) | (0.0) | (0.0) | |
-48.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -10M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
19.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.8M | 0.0 | 0.0 | 0.0 | 0.0 | -1.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-28.7M | (0.0) | (0.0) | (4K) | (0.0) | (0.0) | (0.0) | -447.8K | (8.5M) | (2.5M) | -50.9K | (0.0) | (0.0) | -985.9K | -1.4M | -213.1K | (0.0) | (0.0) | (0.0) | (0.0) | |
FINANCING ACTIVITIES | ||||||||||||||||||||
46.4M | 810K | 0.0 | 31.1M | 10.8M | 12.3M | 10.8M | 0.0 | -54.3K | 0.0 | 31.8M | 427.5K | 143.8K | 4M | 2.3M | 1.3M | 625K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 6M | 0.0 | 0.0 | -550K | -1.9M | 1.9M | 2.4M | -1.1M | 700K | 3.5M | -223.8K | 429.9K | -44.2K | -118.4K | 0.0 | 0.0 | 75K | |
0.0 | 10.3M | 0.0 | -3.8M | 7.1M | 3.7M | -428.5K | -126K | 0.0 | -15.3K | 0.0 | 0.0 | 0.0 | -62.8K | 0.0 | 19.6K | 0.0 | 0.0 | 0.0 | 0.0 | |
46.4M | 11.1M | 0.0 | 33.3M | 17.9M | 16M | 9.9M | 20.1M | 1.8M | 2.4M | 30.7M | 1.1M | 4.5M | 13.1M | 3.4M | 1.3M | 506.6K | 0.0 | 0.0 | 75K | |
CASH FLOW SUMMARY | ||||||||||||||||||||
0.0 | 0.0 | -30.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.2M | 3.7M | -33.2M | 18.8M | 4.3M | 6.2M | -905.3K | 7.3M | -444.3K | -339.3K | 21.6M | -57.1K | 213.6K | 98.4K | 0.0 | -800.0 | 604.0 | 0.0 | 0.0 | 0.0 | |
7.8M | 4.1M | 37.3M | 18.5M | 14.2M | 8M | 8.9M | 1.6M | 2M | 2.3M | 255K | 312.1K | 98.4K | 0.0 | 0.0 | 800.0 | 196.0 | 0.0 | 0.0 | 0.0 | |
9M | 7.8M | 4.1M | 37.3M | 18.5M | 14.2M | 8M | 8.9M | 1.6M | 2M | 21.9M | 255K | 312.1K | 98.4K | 0.0 | 0.0 | 800.0 | 0.0 | 0.0 | 0.0 | |
-16.5M | -7.4M | -2.6M | -14.5M | -13.6M | -9.9M | -10.8M | -12.8M | -10.8M | -5.2M | -9.1M | -1.2M | -4.3M | -12.1M | -2M | -1.1M | -506K | 0.0 | 0.0 | -75K |
SEC Filings
CRVO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | January 08, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 05, 2025 | December 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 07, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 29, 2025 | October 27, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 22, 2025 | October 22, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 08, 2025 | October 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 11, 2025 | August 11, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 08, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your CRVO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.